DNA Damage From Chemo May Help Spur Leukemia's Return

The treatment can achieve acute myeloid leukemia remission, but better options needed, experts say

URL of this page: http://www.nlm.nih.gov/medlineplus/news/fullstory_120745.html
(*this news item will not be available after 04/11/2012)

By Randy Dotinga

Thursday, January 12, 2012

Related MedlinePlus Pages

THURSDAY, Jan. 12 (HealthDay News) -- The chemotherapy used to treat a form of adult leukemia sets a trap that can result in the return of the disease within years, a new study suggests.

The finding confirms the suspicions of specialists who thought chemotherapy drugs could disrupt DNA through mutations and ultimately allow tumor cells to avoid the effects of the medications.

"Chemotherapy drugs are absolutely necessary to get leukemia patients into remission, but we also pay a price in terms of DNA damage," study co-author Dr. Timothy Ley, a professor of oncology at Washington University School of Medicine in St. Louis, said in a university news release.

These drugs "may contribute to disease progression and relapse in many different cancers, which is why our long-term goal is to find targeted therapies based on the mutations specific to a patient's cancer, rather than use drugs that further damage DNA," Ley added.

The type of leukemia in question is known as acute myeloid leukemia. While chemotherapy treatment can send the cancer into remission, 80 percent of patients die within five years. In the United States, about 13,000 cases of acute myeloid leukemia are diagnosed annually, most often in people age 60 and older.

The researchers came to their conclusions after studying the genomes -- the entire DNA, both healthy and cancerous cells -- from eight patients with acute myeloid leukemia. They watched to see what happened after the patients received chemotherapy.

The investigators found that tumors essentially reappeared, according to the report published in the Jan. 11 advance online edition of Nature.

"It's the same tumor coming back but with a twist," co-author Richard Wilson, director of university's Genome Institute, explained in the news release. It "comes back with new mutations that give the cells new strategies for surviving attack by whatever drugs are thrown at them. This makes a lot of sense but it's been hard to prove without whole-genome sequencing."

Commenting on the report, Louis DeGennaro, executive vice president and chief mission officer of the Leukemia & Lymphoma Society, said the study "demonstrates the critical need to identify disease-causing mutations in acute myeloid leukemia so that therapies targeted specifically at these mutations can be developed."

Ultimately, he added, "that would allow us to avoid the use of chemotherapy, which may contribute to cancer relapse."

For now, DeGennaro said, "while current chemotherapy regimens have liabilities, they represent the best treatment currently available and may result in complete remission, which would allow eligible patients to receive a stem cell transplant, the only treatment capable of curing acute myeloid leukemia."

SOURCES: Louis J. DeGennaro, Ph.D., executive vice president and chief mission officer, Leukemia & Lymphoma Society, White Plains, N.Y.; Washington University School of Medicine in St. Louis, news release, Jan. 11, 2012

HealthDay